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This mini-review focuses on a knockdown technology called deoxyribozymes, which has
rarely been utilized in the ﬁeld of neurobiology/neuroscience. Deoxyribozymes are cat-
alytic DNA molecules, which are also entitled DNA enzyme or DNAzyme.This mini-review
presents a description of their development, structure, function, and therapeutic appli-
cation. In addition, information on siRNA, ribozymes, and antisense are given. Further
information on two deoxyribozymes against c-Jun and xylosyltransferase (XT) mRNA are
summarized of which the ﬁrst is important to inﬂuencemany neurological disorders and the
last potentially treats spinal cord injuries (SCIs). In particular, insults to the central nervous
system (CNS) such as SCI generate an inhibitory environment (lesion scar) at the injury site
that prevents the endogenous and therapy-induced axonal regeneration and thereby lim-
its repair strategies. Presently, there are no treatments available. Hence, deoxyribozymes
provide an opportunity for new therapeutics that alter the inhibitory nature of the lesion
scar and thus promote axonal growth in the injured spinal cord.When used cautiously and
within the limits of its ability the deoxyribozyme technology holds promise to become a
major contributing factor in repair strategies of the CNS.
Keywords: central nervous system trauma, brain insult, drug development, DNA enzymes, catalytic DNA, c-Jun,
xylosyltransferase, proteoglycans
INTRODUCTION
Scientists have worked for over 100 years to understand the mech-
anisms that are involved during axonal growth and regeneration
processes. In spite of considerable success no medication is avail-
able. Hence, the development of therapeutics to treat central
nervous system (CNS) trauma such as spinal cord injury (SCI) is
a long awaited intervention in pursuit of ﬁnding a cure for paral-
ysis. Presently, approximately 10,000 people sustain a SCI every
year in Europe; whereas approximately 40 million patients world-
wide are paralyzed due to damage to their spinal cord. About 70%
of all these victims sustained a contusive injury. Most of them are
youngmenwith an average age of 33.4.As a consequence about 2.5
million people must presently live wheelchair-bound or they are
evenworse off (Adams andCavanagh, 2004).An early treatment to
prevent long-term complications after SCI with the goal to accel-
erate recovery is a necessary step toward medicating CNS trauma.
Hence, this review will introduce the deoxyribozyme technology
Abbreviations: AP, activator protein; ATF, activating transcription factor; CNS,
central nervous system; CRE, cAMP responsive element; CREB, cAMP response
element binding protein; CS, chondroitin sulfate; DNA, deoxyribonucleic acid; Dz,
deoxyribozyme; FGF, ﬁbroblast growth factor; GAG, glycosaminoglycan; GnRH,
gonadotropin releasing hormone; IGF, insulin-like growth factor; IL, interleukin; iv,
intravenous; JDP, Jun dimerization protein; JNK, c-Jun N-terminal kinase; LNA,
locked nucleic acid; NF-AT, nuclear factor of activated T-cells; ODN, oligonu-
cleotide; PCNA, proliferating cell nuclear antigen; PG, proteoglycan; PNA, peptide
nucleic acid; PS, phosphorothioated; PTO, PS oligonucleotide; R&D, research and
development; RNA, ribonucleic acid; RZ, ribozyme; SCI, spinal cord injury; SELEX,
systematic evolution of ligands by exponential enrichment; siRNA, small inter-
fering RNA; TLR, toll-like receptor; US, United States; WT, Wilms’ tumor; XT,
xylosyltransferase.
as a potential therapeutic that promotes regeneration and axonal
growth after insults to the brain or spinal cord. Its develop-
ment, structure, function, design, and therapeutic applications
will be reviewed to provide an alternative to common knockdown
agents.
DEOXYRIBOZYME
Single-stranded, catalytic DNA molecules, which are also being
called DNA enzymes or DNAzymes, have been reported not to
exist in nature. Instead they have been developed by Santoro and
Joyce (1997) who used a technique called systematic evolution
of ligands by exponential enrichment (SELEX). Here, a selec-
tion process was used, in which a RNA substrate was provided
to a library of approximately 1014 potential single-stranded DNA
enzymes. Via enrichment of the functional catalytic DNA mole-
cules two deoxyribozymes named 10-23 and 8-17 with a length of
approximately 35 nucleotides were isolated (for review, Silverman,
2005). The catalytic loop structure of the 10-23 deoxyribozyme
contains 13, the one of the 8-17 15 nucleotides, of which each is
surrounded by sequence-speciﬁc binding arms (Figure 1A). To
be able to digest any target mRNA and hence prevent the trans-
lation to a protein these two deoxyribozymes require divalent
metal ions such as Ca2+, Mg2+, Mn2+, Zn2+, or Cu2+. These
metals function as a general base or as a Lewis acid either to
stabilize the transition state of the reaction and/or to assist in
folding of the enzyme into an active conformation (Santoro and
Joyce, 1998). An exception is the deoxyribozymemotif,Na8,which
increases RNA cleavage by 108-fold in the absence of divalent
metals (Geyer and Sen, 1997). Another deoxyribozyme requires
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FIGURE 1 | Structure and digestion mechanism of deoxyribozymes. (A)
Structure of the 10-23 and 8-17 deoxyribozyme.The catalytic loop digest the
target mRNA (marked by the arrow) between an unpaired purine and a
paired pyrimidine nucleotide. Binding to the mRNA occurs mostly via
Watson–Crick base pairing. Note a G-T Hoogsteen base pair in the 8-17
deoxyribozyme (modiﬁed from Santoro and Joyce, 1997). (B)
Transesteriﬁcation of a target mRNA via a deoxyribozyme and divalent
cations generates a 2′3′-cyclic phosphate and a 5′-hydroxyl termini as end
product (modiﬁed from Achenbach et al., 2004).
l-histidine or a closely related analog to catalyze RNA phos-
phoester cleavage (Roth and Breaker, 1998). Target speciﬁcity of
the deoxyribozyme is controlled by the sequence of the binding
arms. The binding arms of both deoxyribozymes form Watson–
Crick base pair interactions of 8–12 nucleotides with their target
mRNA. A phosphodiester linkage in this target mRNA is cleav-
age by deoxyribozymes between an unpaired purine (adenine [A]
or guanine [G]) and a paired pyrimidine (cytosine [C] or uracil
[U]) to an end product of 2′,3′-cyclic phosphate and 5′-hydroxyl
RNA termini (Figure 1B). In case of the 10-23 deoxyribozyme
the required dinucleotides in the target mRNA are G-C, G-U,
A-C, or A-U whereas the 8-17 deoxyribozyme requires solely
A-G as recognition sequence. The order of best to worst sub-
strate cleavage is as follow: rAU= rGU≥ rGrC rArC, whereas
the relatively poor activity of a deoxyribozyme against rArC-
and rGrC-containing substrate can substantially be increased by
chemical modiﬁcations to the binding domain that subtly weaken
the interaction with the substrate. When dG is substituted with
deoxyinosine (dI) such that the three hydrogen bonds between
rC–dG are converted to two hydrogen bonds rC–dI, the biolog-
ical activity of that deoxyribozymes that target rRrC junctions
(R= rA, rG) in the substrate is improved (Cairns et al., 2003). To
prevent deoxyribozyme digestion through serum nucleases, the
following modiﬁcations are the most frequently used: (1) phos-
phorothioated (PS) bases at the 5′ and/or 3′ end; (2) 3′-3′-linked
inverted thymidine or any other inverted nucleotide; (3) locked
nucleic acid (LNA); or (4) phosphoramidated bases (for more
detail on the design of deoxyribozymes please seeAchenbach et al.,
2004).
Deoxyribozymes show high ﬂexibility, speciﬁcity, and low pro-
duction costs, which makes them a valuable asset for treatment of,
e.g., SCI. In addition they have the advantage to be administered
and internalized into cells without using transfection agents, elec-
troporation, or infection albeit utilizing a concentration that does
not induce side effects. Hence, any mRNA that participates in the
inhibitory environment after insult to the CNS can serve as a sub-
strate for digestion. The utilization of deoxyribozymes alone or
in combination with other approaches has the potential to gener-
ate a growth-permissive environment at the lesion site. This holds
promise to enhance axonal regeneration, and thus, increases the
chances of functional recovery.
OTHER KNOCK DOWN TECHNOLOGIES
SMALL INTERFERING RNA
Presently, siRNA is the most frequently used knockdown tech-
nique in science with developments of approximately 21 potential
therapeutics to a variety of diseases (Burnett et al., 2011). The
mechanism of siRNA, which are double-stranded RNA molecules
of usually 21 nucleotides that contain a 3′ overhang of 2 nucleotide
on either end, is well known anddocumented by a plethora of pub-
lications (see reviews: Fire, 1999; Tuschl, 2001; Mello and Conte,
2004). In addition to its role to interfere with the expression of
speciﬁc genes, it also acts in antiviral mechanisms or shaping
the chromatin structure in a genome. siRNA was discovered by
Andrew Fire and Craig Mello, who received the Nobel Prize 2006.
In light of such excitement and success it is surprising that Roche
closed, at the end of last year, all R&D facilities that were working
on identifying siRNAs sequences to treat various diseases and dis-
orders. In addition Novartis terminated a contract withAlnylam, a
company that provides a platform for the identiﬁcation of siRNA
target sequences. However, Novartis continues to work on the 31
siRNAs, which they have internally but they are not interested
in indentifying new sequences. Furthermore, Pﬁzer and Abbott
also demonstrate no further interest in this technology. Instead,
Pﬁzer (New York) in conjunction with Santaris (Horsholm, Den-
mark) formed an alliance to develop an antisense strategy utilizing
PS–LNAs (Pollack, 2011; Schmidt, 2011).
RIBOZYMES
Ribozymes (RZs), mostly used as hammerhead or hairpin RZs in
therapeutic applications, are naturally occurring, single-stranded
RNAmolecules,which contain a catalytic loop structure and cleave
their target RNA in a sequence-speciﬁc manner. They have been
discovered in the 1980s for which Sidney Altman and Thomas
Cech received the Nobel Prize 1989. RZs were the ﬁrst demonstra-
tion that RNA is able to have catalytic/enzymatic properties,which
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lead to the belief that DNA molecules in form of deoxyribozymes
are also able to digest mRNA. Based on the SciClips database 18
potential drug targets are in focus of RZ research. The recogni-
tion sequence of the hammerhead RZs contains a XUN structure,
where X is any base and N is A, C, or U (Haseloff and Gerlach,
1988), whereas hairpin RZs recognize RCN/GUCB with B=C, G,
or U, N= any base and R=G or A as a target sequence (Joseph
et al., 1993).
ANTISENSE
The antisense technology, which was developed in the 1970s
(Zamecnik and Stephenson, 1978), is the trailblazer for gene
knockdown agents used in science and in particular in the ner-
vous system. Here, a single-stranded DNA molecule, an antisense
oligonucleotide (ODN), binds stoichiometrically to the target
mRNA and prevents its transcription, splicing, or translation to
a protein (Eckstein, 2007). If the cell contains RNAse H, the
RNA/DNA hybrid that forms after binding of the antisense ODN
to the target pre-mRNA or mRNA is going to be digested. The
ﬁrst antisense drug, Vitravene, which treated cytomegalovirus-
based retinitis, was approved 1998 and discontinued in 2004 as
the drug’s market shrank (Jones, 2011). Approximately 10 other
antisense drugs are being researched. Furthermore, the follow-
ing proteins c-erbA/rev-erbA (Munroe and Lanzar, 1991), N-myc
(Armstrong and Krystal, 1992), gonadotropin releasing hormone
(GnRH,Wilson et al., 1995),Wilms’ tumor suppressor gene (WT1,
Malik et al., 1995), insulin-like growth factor (IGF-II, Baccarini
et al., 1993; Rivkin et al., 1993), proliferating cell nuclear antigen
(PCNA, Swalla and Jeffery, 1996), hoxa-11 (Hsieh-Li et al., 1995),
and bFGF (FGF-2, Borja et al., 1993) have been observed to be reg-
ulated by their natural antisense ODNs. Modiﬁcations such as PS
oligonucleotides (PTOs), peptide nucleic acids (PNAs), and LNAs
as well as developments of morpholinos have their origin during
antisense development.
THERAPEUTIC APPLICATIONS OF DEOXYRIBOZYMES
Only the 10-23 deoxyribozyme, in particular, with kcat and KM
values comparable to those of naturally occurring ribozymes has
been applied in vivo to inactivate targetmRNAmolecules (Santoro
and Joyce, 1997). As Table 1 demonstrates, 10 in vivo applications
of deoxyribozymes to various target mRNAs exist, however, their
utilization in the neurobiology ﬁeld is quite limited. Therefore,
to focus on rather CNS related applications the mini-review will
focus on c-Jun and xylosyltransferase-1 (XT-1) deoxyribozyme
applications in vivo.
c-Jun is a basic region leucine-zipper transcription factor that
forms homo- and heterodimers, latter in combination with c-fos,
ATF,CREB, steroid hormone receptor, or JDPmembers. It binds to
the AP-1, CRE, or NF-AT consensus sequence in promoter regions
of immediate early genes (see review: Antoniou et al., 2011). The
transcription factor is not only essential to neuronal differentia-
tion but is also a powerful mediator of neuronal apoptotic signal
cascades involving c-Jun N-terminal kinases (JNKs, Kyriakis et al.,
1994). In addition, JNK activation is strongly involved in inﬂam-
matory responses, neurodegeneration, and in the development of
hyperalgesia and allodynia (see mini-review: Gao and Ji, 2008).
Hence, the JNK pathway is an important therapeutic target to
inﬂuence diverse neurological disorders (see review: Antoniou
Table 1 | In vivo application of deoxyribozymes (modified from Isaka, 2007).
Gene target Disease (tissue) Application Reference
GENERAL
Erg-1 Balloon injury (carotid artery) Adventitial (from outside of a vessel) Santiago et al. (1999)
Ligation (carotid artery) Adventitial Lowe et al. (2002)
Restenosis (coronary artery) Endoluminal (from inside a vessel) Lowe et al. (2001)
Tumor growth (breast carcinoma) Transfection, subcutane, intratumoral Fahmy et al. (2003), Mitchell et al. (2004)
Ureteral obstruction (kidney) Interstitial Nakamura et al. (2002)
Myocardial infarction Intramyocardial Bhindi et al. (2006)
TGF-β Glomerulonephritis Renal arterial Isaka et al. (2004)
c-Jun Neovascularization (cornea) Injection, intravitreal Zhang et al. (2004), Khachigian et al. (2002)
Tumor growth (melanoma) Subcutane Zhang et al. (2004)
Tumor growth (squamous cell
carcinoma)
Transfection Zhang et al. (2006)
Inﬂammatory diseases Intravitreal, intradermal, topical Fahmy et al. (2006)
VEGFR-2 Tumor growth (breast carcinoma) Intratumoral Zhang et al. (2002)
TNF-α Myocardial infarction Intraperitoneal Iversen et al. (2001)
VDUP1 Myocardial ischemia Intracardiac Xiang et al. (2005)
PAI-1 Myocardial infarction Intracardiac Xiang et al. (2004)
GATA-3 Asthma (TH2 cells, mast cells,
eosinophils, and epithelial cells)
Intranasal/topical Sel et al. (2008)
ftsZ Sepsis (bacterial cell division) Systemic Tan et al. (2004)
NEUROSCIENCE
Xylosyltransferase-1
(XT-1)
Spinal cord injury Intrathecal Grimpe and Silver (2004), Hurtado et al. (2008)
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et al., 2011). Investigations by Dass and Choong (2010) showed
that the intravenous (iv) administration of a deoxyribozyme to
c-Jun mRNA (Dz13) in a bolus dose or in an in utero assay has no
toxic effect to blood and solid tissues in adult or fetal mice, only a
slight hepatotoxicity was noted with histology.
After insult to the CNS, e.g., SCI an axonal growth inhibitory
environment forms at the injury site. Proteoglycans (PGs) such
as chondroitin sulfate (CS−) PGs constitute a major group of
molecules that participates in this axon growth-inhibition. They
most likely exert their inhibitory effects through glycosaminogly-
can (GAG)-side chains. GAG-chain synthesis is initiated through
an enzyme called XT-1, which attaches a xylose to the PG
core protein. Application of a deoxyribozyme to XT-1 not only
prevents glycosylation of PGs but also avoids the assembly of
the PG core protein into the extracellular matrix. As a conse-
quence,microtransplanted and endogenous severed sensory axons
are able to grow beyond the lesion site because the inhibitory
substrate is reduced (Grimpe and Silver, 2004; Grimpe et al.,
2005; Hurtado et al., 2008). Hence, the deoxyribozyme to XT-1
mRNA holds promise to be a contributing factor in treating CNS
injuries.
Whether deoxyribozymes induce immunostimulatory activ-
ity requires elucidation. Characteristics of single-stranded DNA
molecules to activate such innate immunity are the presence of a
partially (7–10 nucleotides) or completely PS backbone, a poly G
tail at the 3′ end, 5′ end, or both, an internal palindrome sequence
and an unmethylated CpG motif. CpG motifs induce splenic B cell
proliferation,dendritic cellmaturation, antibody production, acti-
vation of T lymphocytes and natural killer cells as well as cytokine
production such as interleukin (IL)-6, IL-12, and interferon γ. The
CpG motif is considered a pathogen-associated molecular pat-
tern, which is recognized by Toll-Like Receptor 9 (TLR9). TLR9
is constitutively expressed only in B cells and plasmacytoid den-
dritic cells in humans and other higher primates (Krug et al.,
2001). Such CpG motifs are likely to occur in deoxyribozymes.
However, no information is available on the immunological sta-
tus of deoxyribozymes. Explicit information on the half-life of
deoxyribozymes in the cell or after systemic administration is
also not available. However, extensive investigations on antisense
PTOs revealed that their plasmahalf-life after iv administration lies
between 30–85min (Stevenson et al., 1999, see review:Wang et al.,
2001)whereaswithin the cell contains their lifespan approximately
2–3 days.
The steady success of the deoxyribozyme technology to gener-
ate potential therapeutics funneled into the foundationof two start
up companies, the US-based CytoGenix Inc. (Tan et al., 2004) and
theGermany-based Sterna Biologicals (Sel et al., 2008),which tests
DNA enzymes in preclinical trials of cancer, sepsis, and asthma
research.
CONCLUSION
All above mentioned knockdown technologies are incapable to
pass the blood–brain or spinal cord-barrier based on their charged
DNA or RNA backbone. Modiﬁcations such as PTOs, PNA, and
LNA are utilized to make up for this deﬁcit. In addition, they pre-
vent exonuclease degradation and increase stability. To direct any
of the molecules to speciﬁc regions of the body, e.g., a tumor, is an
equal challenge to all aforementioned knockdown agents, whereas
uptake into cells without any aid is in favor of single-strandedmol-
ecules. All together one can say each of the knockdown techniques
has its pros and cons depending on scientiﬁc demands or personal
preference. Hence, each agent needs to be evaluated from case to
case. There might not even be one technology to favor but at the
same time, none of these techniques should be overlooked either.
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